Amycretin Calculator
Default: 6mg / 2mL / 1mgAdjust inputs to match your vial
About
What is Amycretin?
Amycretin is a unimolecular GLP-1 / amylin co-agonist in early clinical development by Novo Nordisk. Phase 1b/2a data reported a mean weight reduction of approximately 24% over 36 weeks — the largest effect from any single-molecule GLP-1-class compound observed to date in early trials.
Common vial sizes
| 3 mg | lyophilized powder |
| 6 mg | lyophilized powder |
Reference dose ranges
| 0.5 mg | ≈ 16.7 U-100 units (at 6mg / 2mL) |
| 1 mg | ≈ 33.3 U-100 units (at 6mg / 2mL) |
| 2 mg | ≈ 66.7 U-100 units (at 6mg / 2mL) |
| 3 mg | ≈ 100 U-100 units (at 6mg / 2mL) |
| 6 mg | ≈ 200 U-100 units (at 6mg / 2mL) |
Reconstitution
How it's typically prepared
Reconstitute with BAC water; refrigerate. Limited stability data available.
FAQ
Frequently asked questions
- Is amycretin available?
- Amycretin is investigational as of April 2026. It is in Phase 2 trials for obesity.
Related
Other GLP-1 peptides
Notice
PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.